1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts)
    Meeting Abstract

    Sato, T.; Carvajal, R. D.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L. F.; Nathan, P.; Rioth, M.; Hamid, O.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma
    Meeting Abstract

    Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM)
    Meeting Abstract

    Bai, X.; Shoushtari, A. N.; Warner, A. B.; Quach, H.; Cann, C. G.; Zhang, M.; Pallan, L.; Harvey, C.; Si, L.; Tang, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma
    Meeting Abstract

    Orloff, M.; Carvajal, R. D.; Shoushtari, A. N.; Sacco, J. J.; Schlaak, M.; Watkins, C.; Abdullah, S. E.; Goodall, H.; Butler, M. O.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI)
    Meeting Abstract

    Grimes, J.; Shoushtari, A. N.; Orloff, M.; Khan, S.; Chiuzan, C.; Hsiao, S. J.; McDonnell, D.; Marr, B. P.; Carvajal, R. D.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Propensity weighted indirect treatment comparison of nivolumab (NIVO) versus placebo (PBO) as adjuvant therapy for resected melanoma: A number needed to treat and overall survival analysis
    Meeting Abstract

    Weber, J. S.; Poretta, T.; Stwalley, B.; Sakkal, L.; Du, E. X.; Wang, T.; Chen, Y.; Wang, Y.; Betts, K. A.; Shoushtari, A. N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma
    Meeting Abstract

    Jameson-Lee, M.; Ott, P. A.; Luke, J. J.; Postow, M. A.; Poklepovic, A. S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma
    Meeting Abstract

    Amaria, R. N.; Postow, M. A.; Tetzlaff, M. T.; Ross, M. I.; Glitza, I. C.; McQuade, J. L.; Wong, M. K. K.; Gershenwald, J. E.; Goepfert, R.; Keung, E. Z. Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors
    Meeting Abstract

    Sarfaty, M.; Desjardins, C. A.; Giardina, P.; Bardhan, K.; Pandian, S.; Halley, K.; Halvorsen, E. M.; Callahan, M. K.; Postow, M. A.; Lee, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Disparities in the use of checkpoint inhibitors and CAR T-cell therapy: A systematic review
    Meeting Abstract

    Jutagir, D. R.; Espinosa, A.; Lopez, M.; Rasool, B.; Gomez, T.; Brown, A.; Frankel, C. A.; Loo, K.; Goldberg, J.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save